Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
September 14, 2024 03:30 ET
|
Black Diamond Therapeutics, Inc
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority...
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024 07:30 ET
|
Black Diamond Therapeutics, Inc
Initial Phase 2 data of BDTX-1535 in 2L/3L patients with EGFRm NSCLC on track for later in Q3 2024On track to announce initial Phase 2 data of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC...
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2024 10:00 ET
|
Black Diamond Therapeutics, Inc
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment ...
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 29, 2024 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:30 ET
|
Black Diamond Therapeutics, Inc
Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data...
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 16:05 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of...
Black Diamond Therapeutics Announces Changes to Board of Directors
April 11, 2024 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of...
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
April 07, 2024 18:00 ET
|
Black Diamond Therapeutics, Inc
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R...
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
April 03, 2024 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target...
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 12, 2024 08:00 ET
|
Black Diamond Therapeutics, Inc
Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired...